Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT07057310
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
FEMALE
Age
46 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide or tirzepatide — DRUG
    Semaglutide and tirzepatide will be dosed as per prescription labels
  • Lifestyle modification intervention — BEHAVIORAL
    All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).

Study Details

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Key Dates

Start date
May 1, 2025
Status verified
Jun 2025
Primary completion
Dec 31, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Weight loss medication and standard lifestyle intervention
    Subjects will receive tirzepatide or semaglutide in combination with a standard lifestyle intervention.
  • Active Comparator: Standard lifestyle intervention only
    Subjects will receive standard of care lifestyle intervention only.

Primary Outcome Measure

Physical Function Measure: Short Physical Performance Battery (SPPB) score. [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in FloridaJacksonvilleFlorida32224-

Find similar trials in Jacksonville, FL

By condition
MenopauseObesity / overweight
By specialty
Women's healthFertilityEndocrinologyMetabolic healthWeight loss
By research site
Mayo Clinic in Florida· Jacksonville, FL

Related Studies